US › Healthcare

Lyell Immunopharma Inc (LYEL)

US · Healthcare · Biotechnology

$10.80+0.23%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$4,000

Revenue YoY

-50.0%

Net profit

$-44.8M

EPS

$-1.92

EPS estimate

$-1.94

Net margin

-1,118,875.0%

EPS came in at -1.92 against a street estimate of -1.94 — a beat of 1.0%.

Key statistics

Market cap

$293.1M

Forward P/E

0.0

P/B

1.26

Book value

$9.99

EPS (TTM)

$-12.69

52-week high

$45.00

52-week low

$11.47

50-day MA

$14.04

200-day MA

$20.19

Beta

-0.05

Analyst view

Analysts rate Lyell Immunopharma Inc a hold (0 buy, 3 hold, 1 sell out of 4) with an average price target of $37.88.

Shareholding

Insiders

37.31%

Institutions

54.21%

Largest institutional holders

Fund	Stake
ARCH VENTURE CORP	13.25%
GSK PLC	6.17%
Orland Properties Ltd	3.08%
Vanguard Capital Management, LLC	2.93%
Almitas Capital LLC	2.36%
Foresite Capital Management V, LLC	1.94%
Millennium Management LLC	1.50%
Opaleye Management Inc	1.40%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Lyell Immunopharma Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.